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Background: HPV oncogenes mRNA detection gains momentum as an adjuvant for HPV-related cervical
abnormalities diagnosis, but is based on costly detection assays not allowing viral type targeting.
Objective: To assess detection rate of HPV oncogenes E6/E7 mRNA from cervical specimens using a manual, open
technology, fully customizable protocol and determine whether HPV-related epidemiological features influence
mRNA retrieval. We reviewed literature and compared our retrieval rate with automated technologies.
Methods: We used 60 samples positive for HPV DNA types 16, 18, 31 and/or 45. We extracted mRNA with a
TRizol-based protocol, and tested mRNA purity and concentration using light absorbance. We reverse-transcribed
mRNA into cDNA for E6/7 detection.
Results: HPV oncogenes E6/E7 mRNA was retrieved from 36 (60%) out of 60 specimens. No HPV load-related clinical or
epidemiological feature was significantly associated with mRNA retrieval. Presence of HPV-DNA 16/18 was associated
with mRNA retrieval (OR = 9.08; 95% CI 1.26 to 65.32 for HPV 16; and 18.2; IC95% 1.86 to 391.44 for HPV 18).
Conclusions: The open-technology protocol yielded an mRNA detection rate similar to that of automated
technologies. Advantages are lower costs and target HPV type customization.Introduction
In the last two decades, the detection of Human papillo-
mavirus (HPV) DNA in cervical samples has proven to
be a good diagnostic and risk predictor tool for cervical
intraepithelial neoplasia (CIN) and cervical cancer (Castle
et al. 2011). Some studies suggest that HPV oncogenes E6
and E7 mRNA levels in the uterine cervix may be more
specific early indicators of predisposition to carcinogenesis
than DNA levels (Benevolo et al. 2011; Ratnam et al. 2011;
Winer et al. 2009). This may be due to the fact that the
oncogenic potential of the high-risk HPV types (hr-HPV)
relies on the actions of oncoproteins coded by E6/E7,
which bind to and modulate different gene products, in
particular tumor suppressors p53 and pRb (Halfon et al.
2010; Kraus et al. 2006). These interactions can lead to* Correspondence: leo.m.campbell@gmail.com
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in any medium, provided the original work is pcell cycle control disturbances, and defective DNA repair,
causing genomic instability and increased risk of malig-
nant transformation (Cattani et al. 2009; Münger &
Howley 2002).
However, the potential use of HPV oncogenes' mRNA
detection in clinical practice still needs robust confirma-
tory studies. One of the major limiting factors for the
development of such studies is the fact that in order to
determine mRNA levels in cervical specimens, one must
rely on a handful of detection assays, which display dif-
ferent performance profiles. Most currently marketed
assay options for mRNA detection use proprietary technol-
ogy, and feature a pre-specified and non-customizable set
of target HPV types. The PreTect HPV-Proofer (NorChip)
and the NucliSENS Easy Q HPV (bioMérieux) are based
on the same technology, and detect E6/E7 mRNA expres-
sion from the five most prevalent hrHPV types (16, 18, 31,
33 and 45). Other two tests aim at an expanded HPV
types set: the TaqMan real-time PCR assay, which targetsis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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59) and two low-risk (HPV 6 and 11) types using E6/E7
region primers and probes in a duplex format (Andersson
et al. 2011; Lindh et al. 2007), and the APTIMA HPV
Assay (Gen-Probe) targets mRNA expression of the 14 most
carcinogenic hr-HPV types (Burger et al. 2011; Dockter
et al. 2009). However, the prevalence of HPV types may
vary between female populations and the prespecified set
of HPV types in a given test may prove inadequate in
some epidemiological scenarios. Also importantly, the
use of proprietary technology hinders the development
of assay adaptations to laboratory and economic local
conditions. The costs of the currently available commer-
cial assays may not be compatible with resources available
to many routine laboratories, especially in economically
disadvantaged regions which, paradoxically, are heavily
burdened by HPV-related diseases.
We intend to improve the efficacy and lower the cost of
HPV oncogene detection, in this report we try to demon-
strate how the detection rate of HPV oncogenes E6 and
E7 mRNA from cervical specimens can be assessed using
a manual open technology protocol, and determine whether
the key epidemiological factors related to HPV viral load
influence its mRNA retrieval rate.
Materials and methods
Sample and data collection
This study was carried out at the colposcopy clinics of
Campinas State University (Unicamp), Brazil, a public
health institution dedicated to comprehensive care for
women, was approved by the local Ethics Committee
(Protocol: N° CEP 723/2009) in compliance with the
recommendations of the “Declaration of Helsinki” for
guiding medical doctors in biomedical research involv-
ing human subjects. The samples consisted of cervical
specimens, collected from women who underwent cer-
vical diathermic conization due to HPV-induced squa-
mous lesions at Unicamp’s cervical pathology clinics.
Women were invited to participate while awaiting the
conization procedure. Every research subject signed a
written informed consent stating their compliance with
the study, and an interview was performed concerning
clinical and epidemiological aspects. After that, and im-
mediately before the conization procedure, a cervical
specimen was obtained with an endocervical brush, and
stored in a 1-mL tube containing Specimen Transport
Medium (STM, Qiagen Inc.).
In order to obtain the sample for these experiments we
examined 117 specimens between April and December
2010. We first performed PCR reactions in order to ascer-
tain the presence of HPV DNA using standard protocols
(Swan et al. 1999). Of the 117 original cases 74 were posi-
tive for HPV DNA (PGMY 9/11). We next performed
PCR reactions in order to ascertain the presence of DNAof the following HPV types: 16, 18, 31 and/or 45. Samples
not harboring at least one of the HPV types of interest
were discarded, and the patient excluded from the study.
After completing 60 samples positive for at least one HPV
type, we closed the accrual phase of the study (estimated
sample size, considering 95% confidence intervals and
80% Beta power, for an estimated difference in mRNA
levels of 20% between women harboring different HPV
types, was 58). We then proceeded to the next phase
of the study: detection of the mRNA in the samples.
mRNA extraction
As mentioned earlier, only samples positive for DNA of
HPV types 16, 18, 31 and 45 were tested for mRNA. For
mRNA extraction, an aliquot of 200 ul of STM was sam-
pled (Qiagen) and centrifuged at 13,000 g for 10 min.
The supernatant was removed and 1 mL of the TRizol™
reagent (Invitrogen, Carlsbad, USA) was added to the
cellular pellet, and cells lysed by repeat pipetting and
standing at room temperature for 5 min (TRizol is the
most widely used reagent in the public setting in Brazil,
hence its choice). Subsequently, 200 ul of chloroform
was added and shaken vigorously, standing at room
temperature for 3 min before centrifugation at 12,000 g
for 15 min. The resultant aqueous layer was then trans-
ferred to a new tube. To the aqueous solution, a volume
of 500 μl of isoamyl alcohol was added and mixed by
vortex. The whole mixture stood at −80°C for 2 hours
and 10 min at room temperature and centrifuged at
12,000 g for 10 min. Supernatant was then removed and
1 mL of iced ethanol was added and shaken vigorously.
Finally, the mixture was centrifuged at 7,500 g for
5 min, the supernatant was removed and after the pellet
of mRNA was dry, mRNA was eluted in 30 μl of
mRNAase-free water (DEPC) and stored at −80°C pend-
ing analysis. The mRNA purity and concentration were
determined by the absorbance at 260 nm (A260) and
280 nm (A280) using NanoDrop ND-1000 (Thermo
Fisher Scientific, Waltham, MA).
Type-specific PCR for HPV 16, 18, 31 and 45 oncogenes E6
and E7 mRNA
PCR products were visualized using agarose gel electrophor-
esis. The reactions were performed separately according to
the reagent mixture: five μl of DNA were added to a PCR
mix containing 0.5 pmol of each primer (Table 1), specific-
ally designed by the investigators for the present study,
4.0 mM MgCl2, 0.25 mM dNTPs and 5 units of Taq
platinum in a final 50 μl volume . Every step of the PCR
reactions was similar, except to annealing temperature
which was different for each type HPV. During each
PCR run, samples were tested altogether with one nega-
tive (water) and one positive control (obtained in prior
studies). A 9-min denaturation step at 95°C was followed
Table 1 Primers designed for E6/E7 mRNA detection
HPV Region Size Sequence
16 E6 ± 659 pb 5′ TAAAACTAAGGGCGTAACCG 3′
5′ TCTATTTCATCCTCCTCCTCTG 3′
16 E7 ± 491 pb 5′ ACTGTGTCCTGAAGAAAAGCAA 3′
5′ AACCATCCATTACATCCCGT 3′
18 E6 ± 608 pb 5′ TAGGTTGGGCAGCACATACT 3′
5′ ATACTTGTGTTTCTCTGCGTCG 3′
E7 ± 358 pb 5′ CGACGCAGAGAAACACAAGTAT 3′
5′ ATTGTTGCTTACTGCTGGGAT 3′
31 E6 ± 606 pb 5′ AAGTAGGGAGTGACCGAAAGT 3′
5′ ACAGTGGAGGTCAGTTGCC 3′
E7 ± 437 pb 5′ AGGCACGGCAAGAAAGACT 3′
5′ AAAGAACCAGCCATTACACC 3′
45 E6 ± 659 pb 5′ ATACTACATAAAAAAGGGTG 3′
5′ TCGTAACACAACAGGTCAACA 3′
E7 ± 439 pb 5′ AGGCACGGCAAGAAAGACT 3′
5′ AAAGAACCAGCCATTACACC 3′
Table 2 Recovery of viable E6/E7 mRNA according to key
clinical features of the women and cyto-histological
characteristics of the samples
mRNA E6 or E7
Characteristic neg (%) pos (%) OR (95% CI) p
Age
<30 14 (58.3) 16 (44.4) 4.18 (0.87 to 20.05) 0.073
>30 10 (41.7) 20 (55.6) 1.0
First intercourse
<16 14 (58.3) 19 (52.8) 0.73 (0.2 to 2.72) 0.637
>16 10 (41.7) 17 (47.2) 1.0
Lifetime sex partners
>2 5 (20.8) 9 (25) 0.55 (0.11 to 2.69) 0.461
1-2 19 (79.2) 27 (75) 1.0
Current smoker
Yes 8 (33.3) 11 (30.6) 0.8 (0.2 to 3.18) 0.751
No 16 (66.7) 25 (69.4) 1.0
Cytology
ASC-H or HSIL 19 (79.2) 27 (75) 0.36 (0.06 to 2.02) 0.245
ASC-US or LSIL 5 (20.8) 9 (25) 1.0
Histology
CIN2-CIN3 21 (87.5) 35 (97.2) 5.43 (0.24 to 124.79) 0.290
Cervivitis-CIN1 3 (12.5) 1 (2.8) 1.0
HPV Type-specific mRNA transcription* **
DNA-HPV 16
Positive 17 (40.4) 25 (59.6) 9.08 (1.26 to 65.32) 0.028
DNA HPV 18
Positive 2 (28.5) 5 (71.5) 18.27 (1.86 to 392.44) 0.033
DNA HPV 31
Positive 14 (54.4) 12 (45.6) 3.18 (0.68 to 14.89) 0.142
DNA HPV 45
Positive 5 (50.0) 5 (50.0) 13.45 (0.73 to 246.64) 0.080
*As per study design samples negative for a given HPV type were not re-tested
for that type-specific mRNA; **percentages in rows.
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naturation step at 95°C for 1 min, a primer annealing
step for each HPV type for 1 min, and a chain elong-
ation step at 72°C for 1 minute. The final elongation
step was prolonged by 7 min to ensure complete ampli-
fied DNA extension.
CDNA transcription
The mRNA was reverse-transcribed into first strand cDNA
(SuperScript III First Strand Synthesis System, Invitrogen)
according to the manufacturer’s guidelines. The cDNA
PCR product was amplified as described in the type-
specific PCR section, although with a final volume of
25 μl and 2 μl of cDNA.
Statistical analysis
All statistical analyses were performed with the R Environ-
ment for Statistical Computing (R Project). Significance
was set at 95% (p = 0.05) and 95% confidence intervals
were used (95% CI). We constructed a multivariate regres-
sion model assessing HPV oncogenes E6 and E7 mRNA
retrieval according to clinical features and presence of
HPV DNA of types 16, 18, 31 and/or 45. Odds ratios were
obtained by exponentiation of the regression coefficients.
Results
We retrieved oncogenes E6 and E7 mRNA from 36 (60%)
of the 60 specimens previously found to be positive for the
relevant HPV genotypes. None of the classically viral load -
related clinical and epidemiological features that have been
repeatedly reported in the medical literature was signifi-
cantly associated with mRNA retrieval (Benevolo et al. 2011;Kraus et al. 2006). The presence of HPV 16 and 18 in
the sample was positively associated with mRNA retrieval
(OR = p < 9.08; 95% CI 1.26 to 65.32 for HPV 16; and 18.2;
IC 95% 1.86 to 391.44 for HPV 18). Presence of other
HPV genotypes was not associated to mRNA retrieval at
the same rate, and associations were not significant at
the 95% threshold (Table 2).
Table 3 lists key findings of major studies addressing
mRNA detection rate in HPV DNA positive cervical spec-
imens. Our detection rate of 60% is comparable to that
reported by (Halfon et al. 2010) (68.5%) and (Ratnam et al.
2011) (68%), who used the automated NucliSens Easy Q
HPV Assay BioMerieux and Aptima HPV detection as-
says, respectively. Those detection assays are targeted to
HPV types 16, 18, 31, 33 and 45, which is basically the
Table 3 Studies assessing mRNA retrieval from HPV-DNA positive cervical samples using currently available detection assays
Author Year Detection technique Automation HPV types included in assay E6/E7 mRNA detection rate
Molden 2005 Pre-Tec HPV Proofer NASBA Automated 16 18 31 33 45 98/429 (228%)
Catani 2009 NucliSens Easy Q HPV Assay BioMerieux Automated 16 18 31 33 45 81/180 (45%)
Dockter* 2009 Aptima HPV Assay Tigris DST System Semi-automated 16 18 31 33 35 39 45 51 52 56 58 59 66 and 68 407/443 (919%)
Dockter* 2009 Aptima HPV Assay DST Automated 16 18 31 33 35 39 45 51 52 56 58 59 66 and 68 410/443 (926%)
Halfon 2010 NucliSens Easy Q HPV Assay BioMerieux Automated 16 18 31 33 45 61/89 (68.5%)
Monsonego 2010 Aptima HPV Assay Automated 16 18 31 33 35 39 45 51 52 56 58 59 66 and 68 456/4429 (10.3%)
Benevolo 2011 Pre-Tec HPV Proofer NASBA Automated 16 18 31 33 45 162/464 (36%)
Ratnam 2011 Aptima HPV Assay Automated 16 18 31 33 35 39 45 51 52 56 58 59 66 and 68 964/1418 (68%)
Our study 2012 Homebrew low-cost TRizol protocol Manual 16 18 31 45 36/60 (60%)
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except for HPV 33. (Dockter et al. 2009) compared the
performance of the fully automated Aptima HPV Assay
DST with that of the semi-automated Aptima HPV Assay
Tigris DST System. In samples previously tested for HPV
DNA with Hybrid Capture 2, they achieved 92.6% and
91.9% E6/E7 mRNA detection rates, respectively. How-
ever, those assays target 14 HPV types. (Molden et al.
2005) and (Benevolo et al. 2011) using the Pre-Tec HPV
Proofer NASBA reported 22.8% and 36.0% mRNA detec-
tion rates, respectively.
Discussion
In our study, using open technology protocols (which,
thanks to their relatively low-cost are appropriate for
low-resource settings), we retrieved viable oncogenes E6
and E7 mRNA in almost 60% of the HPV DNA positive
cases. The extraction technique was completely manual.
There are plenty of reports on this subject using auto-
mated our semi-automated detection techniques, with
manufacturer prespecified sets of HPV types included in
the assay. Our mRNA detection rate was comparable to
those reported by most authors using automated mRNA
detection techniques (Benevolo et al. 2011; Cattani et al.
2009). Using proprietary technology protocols, such as
the PreTect HPV-Proofer (NorChip) and the NucliSENS
Easy Q HPV (bioMérieux), studies similar to ours achieved
overall mRNA retrieval rates ranging from 36% to 68%
(Benevolo et al. 2011; Ratnam et al. 2011; Halfon et al.
2010; Cattani et al. 2009; Dockter et al. 2009; Molden
et al. 2005; Monsonego et al. 2010). Therefore, our results
seem to point out to a reliable and not too expensive way
of detecting mRNA. Larger and prospective studies might
well confirm the reliability of open technology protocols
for mRNA detection and underscore its indications in
clinical and laboratory practice. Also worth noting, open
technology manual techniques could allow tailoring exper-
iments to the HPV epidemiological profile (i.e. the most
prevalent HPV types) of the population under scrutiny.
Our study has some limitations, including a lack of
cytology – histology – mRNA detection which was not
included at this time and this also limits the comparison
of our retrieval technique with other methods. Therefore
a comparison with pathological samples from other
publications was also not possible at this time. Another
limitation of our study is that we also did not perform a
comparison with other assays using the same sample
set. Finally, another caveat of this study was that we did
not perform a breakdown of all HPV genotypes present
in each samples (for times more than one), what could point
out to an association of multiple genotypes and mRNA.
However, scientific evidence accumulated from viro-
logical, molecular, clinical and epidemiological studies
has unequivocally demonstrated that cervical cancer isin fact a sequel from a long term unresolved infection by
certain HPV genotypes (Castellsagué 2008). In the largest
multinational studies performed so far, HPV types 16, 18,
31, 33 and 45 were shown to be the most prevalent types
associated with cervical carcinomas, HPV 16 alone found
in more than 50% of cases (Kraus et al. 2006; Bosch et al.
1995). In North India, HPV 16 was by far the commonest
single type in all histological categories. Similar results
have been reported in other studies (Bhatla et al. 2008).
Studies using quantitative type-specific PCR for high-risk
HPV 16, 18, 31, 33, and 45 and low-risk HPV 6 and 11
have shown that HPV 16 can reach much higher viral
loads than the other types and that only for HPV 16 does
increased viral load correlate with increased severity of
cervical disease (Burd 2003). However, questions do re-
main as to how better oncogene mRNA transcription
rates favor the carcinogenic potential of some HPV types,
and to which individual patient characteristics may be in-
volved in the DNA-to-mRNA transcription rates.
Despite the substantial resources spent in cytology
screening and follow-up, cervical cancer is still the 10th
most common cause of cancer death in European women.
In Brazil by contrast, although rapidly declining, cervical
cancer is one of the leading causes of mortality among
women, and the cervical cancer burden is even heavier
in less developed countries. Because cervical cancer is
the only cancer that is almost completely preventable
through regular screening and thus early treatment, im-
provement and expansion of existing screening strategies
and technologies constitutes a main target of the European
Council Recommendation on Cancer Screening (Boulet
et al. 2008). However, many of the proposed screening
strategies, due to resource constraints, may not be
applicable worldwide. A test that can reliably differ-
entiate between transient and persistent infections would
allow additional effective cervical cancer policies targeting
its prevention (Burger et al. 2011) which would be very
welcomed. Detection of mRNA in cervical samples
may probably serve this purpose, for the aforemen-
tioned reasons.
Current lines of evidence reinforce the biological rea-
sons for detecting HPV oncogenes E6 and E7 mRNA.
HPV screening cohort studies have shown that HPV DNA
testing has a higher sensitivity than cytological testing for
the detection of cervical lesions, although it has slightly
lower specificity (Halfon et al. 2010). Its sensitivity for
moderate dysplasia or worse is lower, but the specifi-
city is higher (Cattani et al. 2009; Keegan et al. 2009;
Szarewski et al. 2008). It is well-known that many cer-
vical lesions with moderate or severe dysplasia will regress
spontaneously. Only 31% of colposcopically visible lesions
with severe dysplasia will progress to invasive cancer
within 30 years (McCredie et al. 2008). Changes such as
integration of viral DNA (which stabilizes the expression
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malignant progression of the tumor. Other changes in-
clude the alteration of cellular genes, leading to down-
regulation of tumor suppressor genes and proapoptotic
genes or upregulation of proto-oncogenes or antiapoptotic
genes. These alterations reflect the effects of prolonged
viral gene expression, in particular viral proteins E6 and
E7 (Snijders et al. 2006). In productive HPV infections,
which appear cytologically as LSIL and histologically as
CIN1, the expression of viral E6 and E7 oncogenes is tightly
regulated, with high-level expression only in suprabasal
postmitotic cells. On the other hand, in high-grade CIN
and cancer, E6 and E7 are expressed throughout the thick-
ness of the cervical epithelium (Stanley 2008).
Given the fact that sustained viral oncogenes E6 and
E7 expression is essential for the initiation and mainten-
ance of the transformed phenotype induced by mucosal
high-risk HPVs, several assays have been specifically de-
veloped for the detection of HPV E6⁄E7 mRNA (Snijders
et al. 2010), despite the fact that positivity rates of the
HPV mRNA test are one third that of HPV DNA tests.
Increased knowledge concerning the molecular biology
of cervical carcinogenesis raises expectations that bio-
markers will result in a more accurate diagnosis of cervical
cancer (Horvath et al. 2008). Moreover, the emergence
of molecular medicine has resulted in the increased use
of RNA in clinical diagnostics (Cuschieri et al. 2005).
The identification of persistent infections has become a
primary target for HPV mRNA testing because infections
that do not regress are more likely to lead to cellular
changes of the cervix, pre cancer lesions and/or invasive
cervical cancer.
DNA and mRNA testing may be employed together
for screening to take advantage of the combined higher
sensitivity and specificity these tests have shown; patients
would e.g. then be referred for a biopsy when both tests
were positive (Halfon et al. 2010). Although the combined
use of DNA and mRNA is a promising alternative for the
improvement of molecular-biology based screening of
cervical abnormalities, proprietary technology costs may
preclude its implementation in low-resource settings. Fur-
thermore, the use of assays targeted at a prespecified set
of HPV types may be a waste of resources in regions
with a different HPV type distribution. For the above
mentioned reasons, the potential for clinical applicability
of mRNA detection in low-resource settings seems to
be large.Abbreviations
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